341220
Exo1
A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells by inducing tubulation and collapsing of the Golgi membrane.
别名:
Exo1, 2-(4-Fluorobenzoylamino)methylbenzoate, 2-(4-Fluorobenzoylamino)benzoic Acid Methyl Ester, ER Export Inhibitor I
质量水平
方案
≥95% (HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
white
溶解性
DMF: 25 mg/mL
DMSO: 25 mg/mL
ethanol: 5 mg/mL
methanol: 5 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
Fc1ccc(cc1)C(=O)Nc2c(cccc2)C(=O)OC
InChI
1S/C15H12FNO3/c1-20-15(19)12-4-2-3-5-13(12)17-14(18)10-6-8-11(16)9-7-10/h2-9H,1H3,(H,17,18)
InChI key
KIAPWMKFHIKQOZ-UHFFFAOYSA-N
相关类别
一般描述
A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells (IC50 = 20 µM in BSC1 cells) by inducing tubulation and collapsing of the Golgi membrane and redirecting the traffic back to ER. Acts as a potent and selective modifier of Golgi ARF1 GTPase activity. Unlike another membrane traffic inhibitor Brefeldin A (BFA; Cat. No. 203729), its effect seems to be limited to Golgi, as no effect can be detected on endocytic organelles, such as endosomes and TGN (trans-Golgi network). Its inhibitory mechanism and target(s) appear to be quite different from those of BFA and thus serves as a valuable alternative that complements BFA in membrane traffic studies.
生化/生理作用
Cell permeable: yes
Primary Target
Golgi ARF1 GTPase
Golgi ARF1 GTPase
Product does not compete with ATP.
Reversible: yes
Target IC50: 20 µM inhibiting vesicular traffic from ER to Golgi in BSC1 cells
包装
Packaged under inert gas
制备说明
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他说明
Feng. Y., et al. 2003. Proc. Natl. Acad. Sci. USA100, 6469.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
Toxicity: Harmful (C)
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Chi-Ling Chiang et al.
Nature communications, 14(1), 6692-6692 (2023-10-24)
Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to target high solid tumour burden like PDAC. Here, we report
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持